9 Steps in Pharmaceutical Nitrosamine Risk Assessment
Nitrosamine risk assessment has become a critical part of pharmaceutical impurity control. Since nitrosamine impurities were first identified as a major regulatory concern in medicines, the scientific focus has expanded from well-known small-molecule nitrosamines such as NDMA and NDEA to a much broader range of potential impurities, including nitrosamine drug substance-related impurities (NDSRIs). The challenge […]






